http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2416619-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d5cb7ca92f84a089eb85b0af4202b8de |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2821 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4711 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate | 2006-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81d59382c6dece91e0cd16114887e980 |
| publicationDate | 2011-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2416619-C2 |
| titleOfInvention | Method for in vitro diagnosis of alzheimer's disease using monoclonal antibody |
| abstract | FIELD: chemistry. n SUBSTANCE: invention discloses variants of a monoclonal antibody which identifies epitope in β-amyloid peptide with a VHHQK sequence. Described is a hybridome which produces the said antibody (ECACC 06030101), as well as versions of compositions based on the antibody. Disclosed are versions of the method for in vitro diagnosis based on the antibodies and versions of using the antibody for in vitro diagnosis of Alzheimer's disease using the monoclonal antibody and compositions based thereon. Binding of the antibody with amino acids 12-16 β-amyloid peptide - specifically detects neuritic plaques which are characteristic features of Alzheimer's disease, without detecting diffusion plaques, which are not features of the disease. The monoclonal antibody can be used to detect a subgroup among neuritic plaques, whose composition is characterised by deposits of isoforms of the β-amyloid peptide associated with the progression phase of the disease. The antibody can bind with isoforms of the β-amyloid peptide in a biological fluid such as urine, plasma, blood or spinal fluid. n EFFECT: said properties can be used during in vitro diagnosis of Alzheimer's disease when determining the progression phase of the disease. n 50 cl, 7 dwg, 6 ex |
| priorityDate | 2005-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 236.